The dependence of chemokine-glycosaminoglycan interactions on chemokine oligomerization

Glycobiology

Volumn 26, Issue 3, 2015, Pages 312-326

  Dyer, Douglas P ^a   Salanga, Catherina L ^a   Volkman, Brian F ^b   Kawamura, Tetsuya ^a   Handel, Tracy M ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

chemokine; heparan sulfate; heparin; oligomerization; surface plasmon resonance

Indexed keywords

CHEMOKINE; CHONDROITIN 4 SULFATE; CXCL11 CHEMOKINE; CXCL4 CHEMOKINE; HEPARAN SULFATE; HEPARIN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; RANTES; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; GLYCOSAMINOGLYCAN; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; CHEMOKINE OLIGOMERIZATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN IMMOBILIZATION; PROTEIN PROTEIN INTERACTION; SULFATION; SURFACE PLASMON RESONANCE; BINDING SITE; CELL MOTION; CHEMISTRY; METABOLISM; MOLECULAR MODEL; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE;

BINDING SITES; CELL MOVEMENT; CHEMOKINES; GLYCOSAMINOGLYCANS; HEPARIN; HEPARITIN SULFATE; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; SURFACE PLASMON RESONANCE;

EID: 84959429965     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwv100     Document Type: Article

References (83)

1. Afratis N, Gialeli C, Nikitovic D, Tsegenidis T, Karousou E, Theocharis AD, Pavao MS, Tzanakakis GN, Karamanos NK. 2012. Glycosaminoglycans: Key players in cancer cell biology and treatment. FEBS J. 279:1177-1197.
2. Ali S, O'Boyle G, Mellor P, Kirby JA. 2007. An apparent paradox: Chemokine receptor agonists can be used for anti-inflammatory therapy. Mol Immunol. 44:1477-1482.
3. Ali S, Robertson H, Wain JH, Isaacs JD, Malik G, Kirby JA. 2005. A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation. J Immunol. 175:1257-1266.
4. Allen SJ, Crown SE, Handel TM. 2007. Chemokine: Receptor structure, interactions, and antagonism. Annu Rev Immunol. 25:787-820.
5. Allen SJ, Hamel DJ, Handel TM. 2011. A rapid and efficient way to obtain modified chemokines for functional and biophysical studies. Cytokine. 55:168-173.
6. Amara A, Lorthioir O, Valenzuela A, Magerus A, Thelen M, Montes M, Virelizier JL, Delepierre M, Baleux F, Lortat-Jacob H, et al. 1999. Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. J Biol Chem. 274:23916-23925.
7. Baggiolini M. 1998. Chemokines and leukocyte traffic. Nature. 392:565-568.
8. Baltus T, von Hundelshausen P, Mause SF, Buhre W, Rossaint R, Weber C. 2005. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J Leukoc Biol. 78:435-441.
9. Brule S, Charnaux N, Sutton A, Ledoux D, Chaigneau T, Saffar L, Gattegno L. 2006. The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology. 16:488-501.
10. CampanellaGSV,GrimmJ,Manice LA,Colvin RA,Medoff BD,WojtkiewiczGR, Weissleder R, Luster AD. 2006. Oligomerization of CXCL10 is necessary for endothelial cell presentation and in vivo activity. J Immunol. 177:6991-6998.
11. Cardin AD,Weintraub HJ. 1989. Molecularmodeling of protein-glycosaminoglycan interactions. Arteriosclerosis. 9:21-32.
12. Chang TLY, Gordon CJ, Roscic-Mrkic B, Power C, Proudfoot AEI, Moore JP, Trkola A. 2002. Interaction of the CC-chemokine RANTES with glycosaminoglycans activates a p44/p42 mitogen-activated protein kinasedependent signaling pathway and enhances human immunodeficiency virus type 1 infectivity. J Virol. 76:2245-2254.
13. Charnaux N, Brule S, Chaigneau T, Saffar L, Sutton A, Hamon M, Prost C, Lievre N, Vita C, Gattegno L. 2005. RANTES (CCL5) induces a CCR5-dependent accelerated shedding of syndecan-1 (CD138) and syndecan-4 from HeLa cells and forms complexes with the shed ectodomains of these proteoglycans as well as with those of CD44. Glycobiology. 15:119-130.
14. Charnaux N, Brule S, Hamon M, Chaigneau T, Saffar L, Prost C, Lievre N, Gattegno L. 2005. Syndecan-4 is a signaling molecule for stromal cellderived factor-1 (SDF-1)/CXCL12. FEBS J. 272:1937-1951.
15. Clark-Lewis I, Kim KS, Rajarathnam K, Gong JH, Dewald B, Moser B, Baggiolini M, Sykes BD. 1995. Structure-activity relationships of chemokines. J Leukoc Biol. 57:703-711.
16. Czaplewski LG, McKeating J, Craven CJ, Higgins LD, Appay V, Brown A, Dudgeon T, Howard LA, Meyers T, Owen J, et al. 1999. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants. J Biol Chem. 274:16077-16084.
17. de Paz JL, Moseman EA, Noti C, Polito L, von Andrian UH, Seeberger PH. 2007. Profiling heparin-chemokine interactions using synthetic tools. ACS Chem Biol. 2:735-744.
18. Deepa SS, Yamada S, Zako M, Goldberger O, Sugahara K. 2004. Chondroitin sulfate chains on syndecan-1 and syndecan-4 from normal murine mammary gland epithelial cells are structurally and functionally distinct and cooperate with heparan sulfate chains to bind growth factors. A novel function to control binding of midkine, pleiotrophin, and basic fibroblast growth factor. J Biol Chem. 279:37368-37376.
19. Drury LJ, Ziarek JJ, Gravel S, Veldkamp CT, Takekoshi T, Hwang ST, Heveker N, Volkman BF, Dwinell MB. 2011. Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc Natl Acad Sci USA. 108:17655-17660.
20. Dubrac A, Quemener C, Lacazette E, Lopez F, Zanibellato C, Wu WG, Bikfalvi A, Prats H. 2010. Functional divergence between 2 chemokines is conferred by single amino acid change. Blood. 116:4703-4711.
21. Gangavarapu P, Rajagopalan L, Kolli D, Guerrero-Plata A, Garofalo RP, Rajarathnam K. 2012. The monomer-dimer equilibrium and glycosaminoglycan interactions of chemokine CXCL8 regulate tissue-specific neutrophil recruitment. J Leukocyte Biol. 91:259-265.
22. Haessler U, Pisano M, Wu M, Swartz MA. 2011. Dendritic cell chemotaxis in 3D under defined chemokine gradients reveals differential response to ligands CCL21 and CCL19. Proc Natl Acad Sci USA. 108:5614-5619.
23. Hamel DJ, Sielaff I, Proudfoot AEI, Handel TM. 2009. Chapter-4 interactions of chemokines with glycosaminoglycans. Methods Enzymol. 2009;461:71-102.
24. Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE. 2005. Regulation of protein function by glycosaminoglycans-as exemplified by chemokines. Annu Rev Biochem. 74:385-410.
25. Hirose J, Kawashima H, SwopeWillis M, Springer TA, Hasegawa H, Yoshie O, Miyasaka M. 2002. Chondroitin sulfate B exerts its inhibitory effect on secondary lymphoid tissue chemokine (SLC) by binding to the C-terminus of SLC. Biochim Biophys Acta. 1571:219-224.
26. Hoogewerf AJ, Kuschert GS, Proudfoot AE, Borlat F, Clark-Lewis I, Power CA, Wells TN. 1997. Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry. 36:13570-13578.
27. Jansma AL, Kirkpatrick JP, Hsu AR, Handel TM, Nietlispach D. 2010. NMR analysis of the structure, dynamics, and unique oligomerization properties of the chemokine CCL27. J Biol Chem. 285:14424-14437.
28. Jin H, Shen X, Baggett BR, Kong X, LiWang PJ. 2007. The human CC chemokine MIP-1beta dimer is not competent to bind to the CCR5 receptor. J Biol Chem. 282:27976-27983.
29. Karlsson R, Falt A. 1997. Experimental design for kinetic analysis of proteinprotein interactions with surface plasmon resonance biosensors. J Immunol Methods. 200:121-133.
30. Kohout TA, Nicholas SL, Perry SJ, Reinhart G, Junger S, Struthers RS. 2004. Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem. 279:23214-23222.
31. KolarovaH, Ambruzova B, Svihalkova Sindlerova L, Klinke A, Kubala L. 2014. Modulation of endothelial glycocalyx structure under inflammatory conditions. Mediators Inflamm. 2014:694312.
32. Krieger E, Geretti E, Brandner B, Goger B, Wells TN, Kungl AJ. 2004. A structural and dynamic model for the interaction of interleukin-8 and glycosaminoglycans: Support from isothermal fluorescence titrations. Proteins. 54:768-775.
33. Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ, Wells TN. 1999. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry. 38:12959-12968.
34. Laguri C, Sadir R, Rueda P, Baleux F, Gans P, Arenzana-Seisdedos F, Lortat-Jacob H. 2007. The novel CXCL12gamma isoform encodes an unstructured cationic domain which regulates bioactivity and interaction with both glycosaminoglycans and CXCR4. PLoS ONE. 2:e1110.
35. Lau EK, Paavola CD, Johnson Z, Gaudry J-P, Geretti E, Borlat F, Kungl AJ, Proudfoot AE, Handel TM. 2004. Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: Implications for structure and function in vivo. J Biol Chem. 279:22294-22305.
36. Lawrence R, Lu H, Rosenberg RD, Esko JD, Zhang L. 2008. Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat Methods. 5:291-292.
37. Lawrence R, Olson SK, Steele RE,Wang L,Warrior R, Cummings RD, Esko JD. 2008. Evolutionary differences in glycosaminoglycan fine structure detected by quantitative glycan reductive isotope labeling. J Biol Chem. 283: 33674-33684.
38. Lortat-Jacob H, Grosdidier A, Imberty A. 2002. Structural diversity of heparan sulfate binding domains in chemokines. Proc Natl Acad Sci USA. 99:1229-1234.
39. Maillard L, Saito N, Hlawaty H, Friand V, Suffee N, Chmilewsky F, Haddad O, Laguillier C, Guyot E, Ueyama T, et al. 2014. RANTES/CCL5 mediatedbiological effects depend on the syndecan-4/PKCalpha signaling pathway. Biol Open. 3:995-1004.
40. Martin L, Blanpain C, Garnier P, Wittamer V, Parmentier M, Vita C. 2001. Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry. 40:6303-6318.
41. Middleton J, Neil S,Wintle J, Clark-Lewis I, Moore H, Lam C, Auer M, Hub E, Rot A. 1997. Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell. 91:385-395.
42. Migliorini E, Thakar D, Sadir R, Pleiner T, Baleux F, Lortat-Jacob H, Coche-Guerente L, Richter RP. 2014. Well-defined biomimetic surfaces to characterize glycosaminoglycan-mediated interactions on the molecular, supramolecular and cellular levels. Biomaterials. 35:8903-8915.
43. Mizumoto S, Fongmoon D, Sugahara K. 2013. Interaction of chondroitin sulfate and dermatan sulfate from various biological sources with heparinbinding growth factors and cytokines. Glycoconj J. 30:619-632.
44. Nasser MW, Raghuwanshi SK, Grant DJ, Jala VR, Rajarathnam K, Richardson RM. 2009. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J Immunol. 183:3425-3432.
45. O'Hayre M, Salanga CL, Dorrestein PC, Handel TM. 2009. Phosphoproteomic analysis of chemokine signaling networks. Methods Enzymol. 460:331-346.
46. Oynebraten I, Barois N, Bergeland T, Kuchler AM, Bakke O, Haraldsen G. 2015. Oligomerized, filamentous surface presentation of RANTES/CCL5 on vascular endothelial cells. Sci Rep. 5:9261.
47. Paavola CD, Hemmerich S, Grunberger D, Polsky I, Bloom A, Freedman R, Mulkins M, Bhakta S, McCarley D,Wiesent L, et al. 1998. Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B. J Biol Chem. 273:33157-33165.
48. Patel DD, Koopmann W, Imai T, Whichard LP, Yoshie O, Krangel MS. 2001. Chemokines have diverse abilities to form solid phase gradients. Clin Immunol. 99:43-52.
49. Peterson FC, Elgin ES, Nelson TJ, Zhang F, Hoeger TJ, Linhardt RJ, Volkman BF. 2004. Identification and characterization of a glycosaminoglycan recognition element of the C chemokine lymphotactin. J Biol Chem. 279:12598-12604.
50. Proudfoot AE, Fritchley S, Borlat F, Shaw JP, Vilbois F, Zwahlen C, Trkola A, Marchant D, ClaphamPR,Wells TN. 2001. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem. 276:10620-10626.
51. Proudfoot AEI, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, Wells TNC, Kosco-Vilbois MH. 2003. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA. 100:1885-1890.
52. Rajarathnam K, Sykes BD, Kay CM, Dewald B, Geiser T, Baggiolini M, Clark-Lewis I. 1994. Neutrophil activation by monomeric interleukin-8. Science. 264:90-92.
53. Rauova L, Poncz M, McKenzie SE, Reilly MP, Arepally G, Weisel JW, Nagaswami C, Cines DB, Sachais BS. 2005. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood. 105:131-138.
54. Reitsma S, Oude Egbrink MG, Heijnen VV, Megens RT, Engels W, Vink H, Slaaf DW, van Zandvoort MA. 2011. Endothelial glycocalyx thickness and platelet-vessel wall interactions during atherogenesis. Thromb Haemost. 106:939-946.
55. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. 2007. The endothelial glycocalyx: Composition, functions, and visualization. Pfluegers Arch. 454:345-359.
56. Roscic-Mrkic B, Fischer M, Leemann C, Manrique A, Gordon CJ, Moore JP, Proudfoot AEI, Trkola A. 2003. RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood. 102:1169-1177.
57. Rot A. 1993. Neutrophil attractant/activation protein-1 (interleukin-8) induces in vitro neutrophil migration by haptotactic mechanism. Eur J Immunol. 23:303-306.
58. Salanga CL, Dyer DP, Kiselar JG, Gupta S, Chance MR, Handel TM. 2014. Multiple glycosaminoglycan-binding epitopes of monocyte chemoattractant protein-3/CCL7 enable it to function as a non-oligomerizing chemokine. J Biol Chem. 289:14896-14912.
59. Salanga CL, Handel TM. 2011. Chemokine oligomerization and interactions with receptors and glycosaminoglycans: The role of structural dynamics in function. Exp Cell Res. 317:590-601.
60. Sarabi A, Kramp BK, Drechsler M, Hackeng TM, Soehnlein O, Weber C, Koenen RR, Von Hundelshausen P. 2011. CXCL4L1 inhibits angiogenesis and induces undirected endothelial cellmigration without affecting endothelial cell proliferation and monocyte recruitment. J Thromb Haemost. 9:209-219.
61. Schumann K, Lammermann T, Bruckner M, Legler DF, Polleux J, Spatz JP, Schuler G, Forster R, Lutz MB, Sorokin L, et al. 2010. Immobilized chemokine fields and soluble chemokine gradients cooperatively shape migration patterns of dendritic cells. Immunity. 32:703-713.
62. Severin IC, Gaudry J-P, Johnson Z, Kungl A, Jansma A, Gesslbauer B, Mulloy B, Power C, Proudfoot AEI, Handel T. 2010. Characterization of the chemokine CXCL11-heparin interaction suggests two different affinities for glycosaminoglycans. J Biol Chem. 285:17713-17724.
63. Soria G, Lebel-Haziv Y, Ehrlich M, Meshel T, Suez A, Avezov E, Rozenberg P, Ben-Baruch A. 2012. Mechanisms regulating the secretion of the promalignancy chemokine CCL5 by breast tumor cells: CCL5's 40s loop and intracellular glycosaminoglycans. Neoplasia. 14:1-19.
64. Stoler-Barak L, Moussion C, Shezen E, Hatzav M, Sixt M, Alon R. 2014. Blood vessels pattern heparan sulfate gradients between their apical and basolateral aspects. PLoS ONE. 9:e85699.
65. Stringer SE, Gallagher JT. 1997. Specific binding of the chemokine platelet factor 4 to heparan sulfate. J Biol Chem. 272:20508-20514.
66. Struyf S, Burdick MD, Peeters E, Van den Broeck K, Dillen C, Proost P, Van Damme J, Strieter RM. 2007. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res. 67:5940-5948.
67. Struyf S, Burdick MD, Proost P, Van Damme J, Strieter RM. 2004. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/ CXCL4 and potent inhibitor of angiogenesis. Circ Res. 95:855-857.
68. Struyf S, Salogni L, Burdick MD, Vandercappellen J, Gouwy M, Noppen S, Proost P, Opdenakker G, Parmentier M, Gerard C, et al. 2011. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 ( platelet factor-4 variant) are mediated by CXCR3. Blood. 117:480-488.
69. Sullivan SK, McGrath DA, Grigoriadis D, Bacon KB. 1999. Pharmacological and signaling analysis of human chemokine receptor CCR-7 stably expressed in HEK-293 cells: High-affinity binding of recombinant ligands MIP-3beta and SLC stimulates multiple signaling cascades. Biochem Biophys Res Commun. 263:685-690.
70. Takekoshi T, Ziarek JJ, Volkman BF, Hwang ST. 2012. A locked, dimeric CXCL12 variant effectively inhibits pulmonary metastasis of CXCR4-expressing melanoma cells due to enhanced serum stability. Mol Cancer Ther. 11:2516-2525.
71. Tan JH, Canals M, Ludeman JP, Wedderburn J, Boston C, Butler SJ, Carrick AM, Parody TR, Taleski D, Christopoulos A, et al. 2012. Design and receptor interactions of obligate dimeric mutant of chemokine monocyte chemoattractant protein-1 (MCP-1). J Biol Chem. 287: 14692-14702.
72. Tanino Y, Coombe DR, Gill SE, Kett WC, Kajikawa O, Proudfoot AEI, Wells TNC, Parks WC, Wight TN, Martin TR, et al. 2010. Kinetics of chemokine-glycosaminoglycan interactions control neutrophil migration into the airspaces of the lungs. J Immunol. 184:2677-2685.
73. Trkola A, Gordon C, Matthews J, Maxwell E, Ketas T, Czaplewski L, Proudfoot AE, Moore JP. 1999. The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity. J Virol. 73:6370-6379.
74. Veldkamp CT, Peterson FC, Pelzek AJ, Volkman BF. 2005. The monomerdimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin. Protein Sci. 14:1071-1081.
75. Veldkamp CT, Seibert C, Peterson FC, De la Cruz NB, Haugner JC, Basnet H, Sakmar TP, Volkman BF. 2008. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci Signal. 1:ra4.
76. Wagner L, Yang OO, Garcia-Zepeda EA, Ge Y, Kalams SA, Walker BD, Pasternack MS, Luster AD. 1998. Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature. 391:908-911.
77. Wang L, Fuster M, Sriramarao P, Esko JD. 2005. Endothelial heparan sulfate deficiency impairs L-selectin-and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol. 6:902-910.
78. Wang X, Watson C, Sharp JS, Handel TM, Prestegard JH. 2011. Oligomeric structure of the chemokine CCL5/RANTES from NMR, MS, and SAXS data. Structure. 19:1138-1148.
79. Weber M, Hauschild R, Schwarz J, Moussion C, de Vries I, Legler DF, Luther SA, Bollenbach T, Sixt M. 2013. Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science. 339:328-332.
80. Weber KS, von Hundelshausen P, Clark-Lewis I, Weber PC, Weber C. 1999. Differential immobilization and hierarchical involvement of chemokines in monocyte arrest and transmigration on inflamed endothelium in shear flow. Eur J Immunol. 29:700-712.
81. Xu D, Esko JD. 2014. Demystifying heparan sulfate-protein interactions. Annu Rev Biochem. 83:129-157.
82. Ziarek JJ, Veldkamp CT, Zhang F, Murray NJ, Kartz GA, Liang X, Su J, Baker JE, Linhardt RJ, Volkman BF. 2013. Heparin oligosaccharides inhibit chemokine (CXC motif) ligand 12 (CXCL12) cardioprotection by binding orthogonal to the dimerization interface, promoting oligomerization, and competing with the chemokine (CXC motif ) receptor 4 (CXCR4) N terminus. J Biol Chem. 288:737-746.
83. Zidar DA, Violin JD, Whalen EJ, Lefkowitz RJ. 2009. Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci USA. 106:9649-9654.